Clinical Trial

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-02-03; most recent amendment 2026-07-07.
Status change: Recruiting → Active, Not Recruiting 2026-07-07
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Trial Details
NCT Number NCT06815627
Lead Sponsor Trust Bio-sonics, Inc.
Collaborators: CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH
Conditions Cardiac Diseases
Enrollment 150 participants
Start Date 2025-03-18
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-09